EGFR and non-small cell lung carcinoma: A treatment decision was established in 23% of patients before the first-line therapy and was changed in 32% of patients who progressed to EGFR TKIs, demonstrating that an analysis of cfDNA by Next Generation Sequencing (NGS) improves genetic profiling of advanced NSCLC patients and the use of targeted therapy [20].